AMG 337 clinical trials
Also written AMG 337.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses AMG 337 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AMG 337
- 6
Studies by the year they started
6 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Amgen (3) · NantPharma, LLC (2) · Eastern Cooperative Oncology Group (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses AMG 337 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell SarcomaTerminatedPhase 2NantPharma, LLCNCT03132155Written as AMG 337
- C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal CancerWithdrawnPhase 1/2Eastern Cooperative Oncology GroupNCT02344810Written as c-Met inhibitor AMG 337
- A Study of AMG 337 in Subjects With Advanced Solid TumorsCompletedPhase 1AmgenNCT01253707Written as AMG 337
- A Phase 1/2 Study Evaluating AMG 337 in Asian SubjectsCompletedPhase 1/2AmgenNCT02096666Written as AMG 337
- QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid TumorsWithdrawnPhase 2NantPharma, LLCNCT03147976Written as AMG 337
- Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid TumorsTerminatedPhase 2AmgenNCT02016534Written as AMG 337
Codes
What other systems call AMG 337 · ClinicalTrials.gg INT000519
- UNII (FDA) 08WG8S0L8DAMG-337Confirmed FDA, Wikidata
- Wikidata Q27456004AMG-337Confirmed FDA, Wikidata
- NCI Thesaurus C95203c-Met Inhibitor AMG 337One source FDA
- DrugBank DB15639One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 08WG8S0L8D | AMG-337 | Confirmed FDA, Wikidata |
| Wikidata | Q27456004 | AMG-337 | Confirmed FDA, Wikidata |
| NCI Thesaurus | C95203 | c-Met Inhibitor AMG 337 | One source FDA |
| DrugBank | DB15639 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.